Assessing candidate serum biomarkers for alzheimer's disease: A longitudinal study

Journal of Alzheimer's Disease

Volumn 30, Issue 2, 2012, Pages 311-321

  Zabel, Matthew ^a   Schrag, Matthew ^a,d   Mueller, Claudius ^b   Zhou, Weidong ^b   Crofton, Andrew ^a   Petersen, Floyd ^c   Dickson, April ^a   Kirsch, Wolff M ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c LOMA LINDA UNIVERSITY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C1 inhibitor; cerebral amyloid angiopathy; complement C4; plasma; prospective

Indexed keywords

ALPHA 2 MACROGLOBULIN; AMYLOID P COMPONENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CD5 ANTIGEN; CERULOPLASMIN; CLUSTERIN; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; GELSOLIN; INTER ALPHA TRYPSIN INHIBITOR; PREALBUMIN; VITAMIN D BINDING PROTEIN;

AGED; ALZHEIMER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LONGITUDINAL STUDY; MALE; MASS SPECTROMETRY; MILD COGNITIVE IMPAIRMENT; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TANDEM MASS SPECTROMETRY; VASCULAR AMYLOIDOSIS;

EID: 84861507856     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-112012     Document Type: Review

References (49)

1. Song F, Poljak A, Smythe GA, Sachdev P (2009) Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev 61, 69-80.
2. Mattsson N, Zetterberg H, Blennow K (2010) Lessons from multicenter studies on CSF biomarkers for Alzheimer's disease. Int J Alzheimers Dis 2010, pii: 610613.
3. Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trajanowski JQ, Blennow K (2010) Biological markers of amyloid beta-related mechanismsinAlzheimer's disease. Exp Neurol 223, 334-346.
4. German DC, Gurnani P, Nandi A, Garner HR, Fisher W, Diaz-Arrastia R, O'Suilleabhain P, Rosenblatt KP (2007) Serum biomarkers for Alzheimer's disease: Proteomic discovery. Biomed Pharmacother 61, 383-389. (Pubitemid 47239345)
5. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362. (Pubitemid 46425689)
6. Kirsch W, McAuley G, Holshouser B, Petersen F, Ayaz M, Vinters HV, Dickson C, Haacke EM, Britt W 3rd, Larseng J, Kim I, Mueller C, Schrag M, Kido D (2009) Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia. J Alzheimers Dis 17, 599-609.
7. Mueller C, Zhou W, Vanmeter A, Heiby M, Magaki S, Ross MM, Espina V, Schrag M, Dickson C, Liotta LA, Kirsch WM (2010) The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease. J Alzheimers Dis 19, 1081-1091.
8. Petersen RC, Smith GE, Warin SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308. (Pubitemid 29120227)
9. Elias JE, Haas W, Faherty BK, Gygi SP (2005) Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations. Nat Methods 2, 667-675. (Pubitemid 41223093)
10. Perrin R, Fagan A, Holtzman D (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461, 916-922.
11. Yanamadala V, Friedlander RM (2010) Complementinneuro-protection and neurodegeneration. Trends Mol Med16, 69-76.
12. Terai K, Walker DG, McGeer EG, McGeer PL (1997) Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res 769, 385-390. (Pubitemid 27461477)
13. Yasojima K, Schwab C, McGeer EG, McGeer PL (1999) Up-regulated production and activationofthe complement system in Alzheimer's disease brain. Am J Pathol 154, 927-936. (Pubitemid 29122612)
14. Walker DG, Dalsing-Hernandez JE, Lue LF (2008) Human postmortem brain-derived cerebrovascular smooth muscle cells express all genes of the classical complement pathway: A potential mechanism for vascular damage in cerebral amyloid angiopathy and Alzheimer's disease. Microvasc Res 75, 411-419. (Pubitemid 351508284)
15. Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, Smith C, Kupchak P, Kireeva I, Ingratta L, Jackowski G (2004) Mining biomarkers in human sera using proteomic tools. Proteomics 4, 244-256. (Pubitemid 38140889)
16. Giometto B, Argentiero V, Sanson F, Ongaro G, Tavolato B (1988) Acute-phase proteins in Alzheimer's disease. Eur Neurol 28, 30-33. (Pubitemid 18063981)
17. Cutler P, Akuffo EL, Bodnar WM, Briggs DM, Davis JB, Debouck CM, Fox SM, Gibson RA, Gormley DA, Hol-brook JD, Hunter AJ, Kinsey EE, Prinjha R, Richardson JC, Roses AD, Smith MA, Tsokanas N, Wille DR, Wu W, Yates JW, Gloger IS (2008) Proteomic identification and early validationof complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin Appl 2, 467-477. (Pubitemid 351566256)
18. Hughes SR, Khorkova, Goyal S, Knaeblein J, Heroux J, Riedel NG (1998) Alpha2 macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci USA 95, 3275-3280. (Pubitemid 28135892)
19. Du Y, Ni B, Glinn M, Dodel RC, Bales KR, Zhang Z, Hyslop PA, Paul SM (1997) Alpha2 Macroglobulin as a beta-amyloid peptide-binding plasma protein. J Neurochem 69, 299-305. (Pubitemid 27274185)
20. Thambisetty M, Hye A, Foy C, Daly E, Glover A, Cooper A, Simmons A, Murphy D, Lovestone S (2008) Proteome based identificationof plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol 255, 1712-1720.
21. Licastro F, Parnetti L, Morini MC, Davis LJ, Cucinotta D, Gaiti A, Senin U (1995) Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serumofpatients with probable Alzheimer disease. Alzheimer Dis Assoc Disord 9, 112-118.
22. Licastro F, Morini MC, Polazzi E, Davis LJ (1995) Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer's disease: An acute phase reactant without the peripheral acute phase response. J Neuroimmunol 57, 71-75.
23. Petersen RC (2004) Mild cognitive impairmentasadiagnostic entity. J Intern Med 256, 183-194.
24. Liao PC, Yu L, Kuo CC, Lin CJ, Kuo YM (2007) Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease. Proteomics Clinical Applications 1, 506-512.
25. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042-3050. (Pubitemid 44684524)
26. Matsubara E, Amari M, Shoji M, Harigaya Y, Yaguchi H, Okamoto K, Hirai S (1989) Serum concentrattion of alpha 1 antichymotrypsin is elevated in patients with senile dementia of the Alzheimer type. Prog Clin Biol Res 317, 707-714.
27. Matsubara E, Hirai S, Amari M, Shoji M, Yamaguchi H, Okamoto K, Ishiguro K, Harigaya Y, Wakabayashi K (1990) Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 28, 561-570.
28. Brugge K, Katzman R, Hill LR, Hansen LA, Saitoh T (1992) Serological alpha 1 antichymotrypsin in Down's Syndrome and Alzheimer's disease. Ann Neurol 32, 193-197.
29. Hinds TR, Kukull WA, Van Belle G, Schellenberg GD, Vil-lacres EC, Larson EB (1994) Relationship between serum alpha 1 antichymotrypsin and Alzheimer's disease. Neurobiol Aging 15, 21-27.
30. Lieberman J, Schleissner L, Tachiki KH, Kling AS (1995) Serum alpha 1 antichymotrypsin level as a marker of Alzheimer-type dementia. Neurobiol Aging 16, 747-573.
31. Altstiel LD, Lawlor B, Mohs R, Schmeidler J, Dalton A, Mehta P, Davis K (1995) Elevated alpha1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients. Dementia 6, 17-20.
32. Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LM (2000) Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: Peripheral inflammation or signals from the brain? J Neuroimmunol 103, 97-102. (Pubitemid 30058259)
33. Licastro F, Pedrini S, Ferri C, Casadei V, Govoni M, Pes-sion A, Sciacca FL, Veglia F, Annoni G, Bonafe M, Olivieri F, Franceschi C, Grimaldi LM (2000) Gene polymorphism affecting alpha 1 antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol48, 388-391.
34. McIlroy N, Vahidassr MD, Savage DA, Lloyd F, Patterson CC, Lawson JT, Passmore AP (2000) Association of serum AACT levels and AACT signal polymorphism with late-onset Alzheimer's disease in Northern Ireland. Int J Geriatr Psychiatry 15, 260-266. (Pubitemid 30179178)
35. DeKosky ST, Ikonomovic MD, Wang X, Farlow M, Wis-niewski S, Lopez OL, Becker JT, Saxton J, Klunk WE, Sweet R, Kaufer DI, Kamboh MI (2003) Plasma and cerebrospinal fluid alpha1 antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment. Ann Neurol53, 81-90. (Pubitemid 36083832)
36. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, Perez J, Crowther DC, Lomas DA, Janciauskiene SM (2007) Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69, 1569-1579. (Pubitemid 350287140)
37. Porcellini E, Davis EJ, Chiappelli M, Ianni E, Di Stefano G, Forti P, Ravaglia G, Licastro F (2008) Elevated plasma levels of alpha-1-anti- chymotrypsin in age-related cognitive decline and Alzheimer's disease; a potential therapeutic target. Curr Pharm Des 14, 2659-2664.
38. Furby A, Leys D, Delacourte A, Buee L, Soetaert G, Petit H (1991) Are alpha-1 antichymotrypsin and inter-alpha-trypsin inhibitor peripheral markers of Alzheimer's disease? J Neurol Neurosurg Psychiatry 54, 469.
39. Pirtilla T, Mehta PD, Frey H, Wisniewski HM (1994) Alpha 1-antichymotrypsin and IL 1 beta are not increased in CSF or serum in Alzheimer's disease. Neurobiol Aging 15, 313-317.
40. Licastro F, Sirri V, Trere D, Davis LJ (1997) Monomeric and polymeric forms of alpha-1 antichymotrypsin in sera from patients with probable late onset Alzheimer's disease. Dement Geriatr Cogn Disord 8, 337-342. (Pubitemid 27453703)
41. Mehta N, Uchino K, Fakhran S, Sattar MA, Branstetter BF, Au K, Navratil JS, Paul B, Lee M, Gallagher KM, Manzi S, Ahearn JM, Kao AH (2008) Platelet C4d is associated with acute ischemic stroke and stroke severity. Stroke 39, 3236-3241.
42. Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, Loveless S, Robertson NP, Morgan BP (2010) Complement regulator factor H as a serum biomarker of multiple sclerosis disease. Brain 133, 1602-1611.
43. Verwey NA, Schuitemaker A, van der Flier WM, Mulder SD, Mulder C, Hack CE, Scheltens P, Blankenstein MA, Veer-huis R (2008) Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 26, 522-527.
44. Kessler H, Pajonk FG, Meisser P, Scheider-Axmann T, Hoffmann KH, Supprian T, Herrmann W, Obeid R, Multhaup G, Falkai P, Bayer TA (2006) Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplas-min in patients with Azheimer's disease. J Neural Transm 113, 1763-1769. (Pubitemid 44657672)
45. Squitti R, Quattrocchi CC, Forno GD, Antuono P, Wekstein DR, Capo CR, Salustri C, Rossini PM (2007a) Ceruloplasmin (2-D PAGE) pattern and copper contentinserumofAlzheimer disease patients. Biomark Insights 1, 205-213.
46. Squitti R, Ventriglia M, Barbati G, Cassetta E, Ferreri F, Dal Forno G, Ramires S, Zappasodi F, Rossini PM (2007b) Free copper in serum of Alzheimer's disease patients correlates with markers of liver function. J Neural Transm 114, 1589-1594. (Pubitemid 350212005)
47. Liu HC, Hu CJ, Chang JG, Sung SM, Lee LS, Yuan RY, Leu SJ (2006) Proteomic identification of lower apolipoprotein A-1 in Alzheimer's disease. Dement Geriatr Cogn Disord 21, 155-161.
48. Scacchi R, Gambina G, Ruggeri M, Martini MC, Ferrari G, Silvestri M, Schiavon R, Corbo RM (1999) Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. Neurosci Lett 259, 33-36. (Pubitemid 29051535)
49. Kayshap RS, Nayak AR, Deshpande PS, Kabra D, Purohit HJ, Taori GM, Daginawala HF (2009) Inter-alpha trypsin inhibitor heavy chain 4 is a novel marker of acute ischemic stroke. Clin Chim Acta 402, 160-163.